Post-translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases

Abstract

Posttranslational modifications (PTMs) act as rapid, reversible switches that reshape protein activity, stability, and interactome, thereby governing virtually every physiological cue from signal transduction to epigenetic memory. Mass spectrometry-based proteomics has considerably extended our knowledge about the occurrence and dynamics of PTMs. Pinpointing disease- or physiology-specific PTM sites remains an open challenge. As a biological process with well-defined stage-specific markers and a precise endpoint, erythropoiesis is orchestrated by the complex interplay of multiple PTM-regulatory networks, making it an ideal model for dissecting the spatiotemporal dynamics, quantitative thresholds, and crosstalk of PTMs. This review delineates the applications, detection, and prediction technologies of PTMs, with an emphasis on the mechanisms of phosphorylation, ubiquitination, methylation, SUMOylation, glycosylation, and acetylation in both physiological and pathological processes. Dissecting PTM circuitry driving erythroid specification and maturation, we show how its perturbation triggers disease, clarifying PTM roles. Additionally, we have investigated the progress made in the clinical translation and drug development of the PTMs field, emphasizing the potential of PTMs in the field of precision medicine as well as the existing challenges. This review aims to provide new insights and perspectives for the study of PTMs.

Keywords

clinical translation / erythroid disorders / mass spectrometry / posttranslational modifications / signaling cascades

References

[1] M. J. Suskiewicz, “The Logic of Protein Post-Translational Modifications (PTMs): Chemistry, Mechanisms and Evolution of Protein Regulation Through Covalent Attachments,” BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology 46, no. 3 (2024): e2300178.

[2] J. M. Lee, H. M. Hammarén, M. M. Savitski, and S. H. Baek, “Control of Protein Stability by Post-Translational Modifications,” Nature Communications 14, no. 1 (2023): 201.

[3] Y. W. Lin, “Structure and Function of Heme Proteins Regulated by Diverse Post-Translational Modifications,” Archives of Biochemistry and Biophysics 641 (2018): 1–30.

[4] F. Yan, M. Qian, Q. He, H. Zhu, and B. Yang, “The Posttranslational Modifications of Hippo-YAP Pathway in Cancer,” Biochimica et Biophysica Acta General Subjects 1864, no. 1 (2020): 129397.

[5] H. Han, Y. A. Rim, and J. H. Ju, “Recent Updates of Stem Cell-Based Erythropoiesis,” Human Cell 36, no. 3 (2023): 894–907.

[6] A. M. N. Silva, R. Vitorino, M. R. M. Domingues, C. M. Spickett, and P. Domingues, “Post-Translational Modifications and Mass Spectrometry Detection,” Free Radical Biology & Medicine 65 (2013): 925–941.

[7] E. S. Witze, W. M. Old, K. A. Resing, and N. G. Ahn, “Mapping Protein Post-Translational Modifications With Mass Spectrometry,” Nature Methods 4, no. 10 (2007): 798–806.

[8] J. Brandi, R. Noberini, T. Bonaldi, and D. Cecconi, “Advances in Enrichment Methods for Mass Spectrometry-Based Proteomics Analysis of Post-Translational Modifications,” Journal of Chromatography A 1678 (2022): 463352.

[9] K. A. Brown, J. A. Melby, D. S. Roberts, and Y. Ge, “Top-Down Proteomics: Challenges, Innovations, and Applications in Basic and Clinical Research,” Expert Review of Proteomics 17, no. 10 (2020): 719–733.

[10] G. Mann, P. Sulkshane, P. Sadhu, T. Ziv, M. H. Glickman, and A. Brik, “Antibody for Serine 65 Phosphorylated Ubiquitin Identifies PLK1-Mediated Phosphorylation of Mitotic Proteins and APC1,” Molecules (Basel, Switzerland) (Basel, Switzerland) 27, no. 15 (2022): 4867.

[11] M. R. Bryan Iii, X. Tian, J. H. Tseng, et al., “Development and Characterization of Novel Anti-Acetylated Tau Monoclonal Antibodies to Probe Pathogenic Tau Species in Alzheimer's Disease,” Acta Neuropathologica Communications 12, no. 1 (2024): 163.

[12] R. A. Burt, B. Dejanovic, H. J. Peckham, et al., “Novel Antibodies for the Simple and Efficient Enrichment of Native O-GlcNAc Modified Peptides,” Molecular & Cellular Proteomics: MCP 20 (2021): 100167.

[13] D. Li, L. Wang, B. F. Maziuk, X. Yao, B. Wolozin, and Y. K. Cho, “Directed Evolution of a Picomolar-Affinity, High-Specificity Antibody Targeting Phosphorylated Tau,” Journal of Biological Chemistry 293, no. 31 (2018): 12081–12094.

[14] K. Kasahara, R. Kawade, M. Nakakido, et al., “Unveiling the Structural Mechanisms Behind High Affinity and Selectivity in Phosphorylated Epitope-Specific Rabbit Antibodies,” Journal of Biological Chemistry 300, no. 12 (2024): 107989.

[15] F. M. S. Oliveira, S. Mereiter, P. Lönn, et al., “Detection of Post-Translational Modifications Using Solid-Phase Proximity Ligation Assay,” New Biotechnology 45 (2018): 51–59.

[16] C. Poulard, J. Jacquemetton, J. Valantin, I. Treilleux, and M. Le Romancer, “Proximity Ligation Assay Allows the Detection, Localization, and Quantification of Protein Arginine Methylation in Fixed Tissue,” Journal of Visualized Experiments: JoVE no. 185 (2022).

[17] O. Söderberg, M. Gullberg, M. Jarvius, et al., “Direct Observation of Individual Endogenous Protein Complexes in Situ by Proximity Ligation,” Nature Methods 3, no. 12 (2006): 995–1000.

[18] R. Arlinghaus, M. Iba, E. Masliah, M. R. Cookson, and N. Landeck, “Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay,” Journal of Parkinson's Disease 13, no. 2 (2023): 255–270.

[19] A. El Kaoutari, N. A. Fraunhoffer, S. Audebert, et al., “Pancreatic Ductal Adenocarcinoma Ubiquitination Profiling Reveals Specific Prognostic and Theranostic Markers,” EBioMedicine 92 (2023): 104634.

[20] L. Elfineh, C. Classon, A. Asplund, U. Pettersson, M. Kamali-Moghaddam, and S. B. Lind, “Tyrosine Phosphorylation Profiling via in Situ Proximity Ligation Assay,” BMC Cancer 14 (2014): 435.

[21] P. Pratyush, S. Pokharel, S. Schulze, L. Bramer, R. H. Newman, and D. B. Kc, “Large Language Model (LLM)-Based Advances in Prediction of Post-Translational Modification Sites in Proteins,” Methods in Molecular Biology (Clifton, NJ) 2941 (2025): 313–355.

[22] S. Ramazi and J. Zahiri, “Posttranslational Modifications in Proteins: Resources, Tools and Prediction Methods,” Database: The Journal of Biological Databases and Curation 2021 (2021): baab012.

[23] G. Cheng, Q. Chen, and R. Zhang, “Prediction of Phosphorylation Sites Based on Granular Support Vector Machine,” Granular Computing 6 (2021): 107–117.

[24] M.-X. Zhao, Q. Chen, F. Li, S. Fu, B. Huang, and Y. Zhao, “Protein Phosphorylation Database and Prediction Tools,” Briefings in Bioinformatics 24, no. 2 (2023): bbad090.

[25] N. Blom, S. Gammeltoft, and S. Brunak, “Sequence and Structure-Based Prediction of Eukaryotic Protein Phosphorylation Sites,” Journal of Molecular Biology 294, no. 5 (1999): 1351–1362.

[26] F. Luo, M. Wang, Y. Liu, X. M. Zhao, and A. Li, “DeepPhos: Prediction of Protein Phosphorylation Sites With Deep Learning,” Bioinformatics (Oxford, England) 35, no. 16 (2019): 2766–2773.

[27] X. Wang, Z. Zhang, C. Zhang, X. Meng, X. Shi, and P. Qu, “TransPhos: A Deep-Learning Model for General Phosphorylation Site Prediction Based on Transformer-Encoder Architecture,” International Journal of Molecular Sciences 23, no. 8 (2022): 4263.

[28] M. Chen, W. Zhang, Y. Gou, et al., “GPS 6.0: An Updated Server for Prediction of Kinase-Specific Phosphorylation Sites in Proteins,” Nucleic Acids Research 51, no. W1 (2023): W243–W250.

[29] J. Song, H. Wang, J. Wang, et al., “PhosphoPredict: A Bioinformatics Tool for Prediction of Human Kinase-Specific Phosphorylation Substrates and Sites by Integrating Heterogeneous Feature Selection,” Scientific Reports 7, no. 1 (2017): 6862.

[30] M. Wu, Y. Yang, H. Wang, and Y. Xu, “A Deep Learning Method to More Accurately Recall Known Lysine Acetylation Sites,” BMC Bioinformatics [Electronic Resource] 20, no. 1 (2019): 49.

[31] G. Chen, M. Cao, K. Luo, L. Wang, P. Wen, and S. Shi, “ProAcePred: Prokaryote Lysine Acetylation Sites Prediction Based on Elastic Net Feature Optimization,” Bioinformatics (Oxford, England) 34, no. 23 (2018): 3999–4006.

[32] W. Deng, C. Wang, Y. Zhang, et al., “GPS-PAIL: Prediction of Lysine Acetyltransferase-Specific Modification Sites From Protein Sequences,” Scientific Reports 6 (2016): 39787.

[33] M. Khandelwal and R. Kumar Rout, “DeepPRMS: Advanced Deep Learning Model to Predict Protein Arginine Methylation Sites,” Briefings in Functional Genomics 23, no. 4 (2024): 452–463.

[34] M. Chaudhari, N. Thapa, K. Roy, R. H. Newman, H. Saigo, and B. K. C. Dukka, “DeepRMethylSite: A Deep Learning Based Approach for Prediction of Arginine Methylation Sites in Proteins,” Molecular Omics 16, no. 5 (2020): 448–454.

[35] P. Radivojac, V. Vacic, C. Haynes, et al., “Identification, Analysis, and Prediction of Protein Ubiquitination Sites,” Proteins 78, no. 2 (2010): 365–380.

[36] H. Fu, Y. Yang, X. Wang, H. Wang, and Y. Xu, “DeepUbi: A Deep Learning Framework for Prediction of Ubiquitination Sites in Proteins,” BMC Bioinformatics [Electronic Resource] 20, no. 1 (2019): 86.

[37] S. C. Pakhrin, K. F. Aoki-Kinoshita, D. Caragea, and D. B. Kc, “DeepNGlyPred: A Deep Neural Network-Based Approach for Human N-Linked Glycosylation Site Prediction,” Molecules (Basel, Switzerland) (Basel, Switzerland) 26, no. 23 (2021): 7314.

[38] S. C. Pakhrin, S. Pokharel, K. F. Aoki-Kinoshita, et al., “LMNglyPred: Prediction of Human N-Linked Glycosylation Sites Using Embeddings From a Pre-Trained Protein Language Model,” Glycobiology 33, no. 5 (2023): 411–422.

[39] S. C. Pakhrin, N. Chauhan, S. Khan, J. Upadhyaya, M. R. Beck, and E. Blanco, “Prediction of Human O-Linked Glycosylation Sites Using Stacked Generalization and Embeddings From Pre-Trained Protein Language Model,” Bioinformatics (Oxford, England) 40, no. 11 (2024): btae643.

[40] G. Taherzadeh, M. Campbell, and Y. Zhou, “Computational Prediction of N- and O-Linked Glycosylation Sites for Human and Mouse Proteins,” Methods in Molecular Biology (Clifton, NJ) 2499 (2022): 177–186.

[41] S. Khan, S. A. AlQahtani, S. Noor, and N. Ahmad, “PSSM-Sumo: Deep Learning Based Intelligent Model for Prediction of Sumoylation Sites Using Discriminative Features,” BMC Bioinformatics [Electronic Resource] 25, no. 1 (2024): 284.

[42] Y. Gou, D. Liu, M. Chen, et al., “GPS-SUMO 2.0: An Updated Online Service for the Prediction of SUMOylation Sites and SUMO-Interacting Motifs,” Nucleic Acids Research 52, no. W1 (2024): W238–W247.

[43] Y. Li, Y. Huang, and T. Li, “PTM-X: Prediction of Post-Translational Modification Crosstalk Within and Across Proteins,” Methods in Molecular Biology (Clifton, NJ) 2499 (2022): 275–283.

[44] H. F. Liu and R. Liu, “Structure-Based Prediction of Post-Translational Modification Cross-Talk Within Proteins Using Complementary Residue- and Residue Pair-Based Features,” Briefings in Bioinformatics 21, no. 2 (2020): 609–620.

[45] Y. X. Huang and R. Liu, “Improved Prediction of Post-Translational Modification Crosstalk Within Proteins Using DeepPCT,” Bioinformatics (Oxford, England) 40, no. 12 (2024): btae675.

[46] F. Zhu, L. Deng, Y. Dai, et al., “PPICT: An Integrated Deep Neural Network for Predicting Inter-Protein PTM Cross-Talk,” Briefings in Bioinformatics 24, no. 2 (2023): bbad052.

[47] S. Wang, A. O. Osgood, and A. Chatterjee, “Uncovering Post-Translational Modification-Associated Protein-Protein Interactions,” Current Opinion in Structural Biology 74 (2022): 102352.

[48] H. Huang, C. N. Arighi, K. E. Ross, et al., “iPTMnet: An Integrated Resource for Protein Post-Translational Modification Network Discovery,” Nucleic Acids Research 46, no. D1 (2018): D542–D550.

[49] X. Hong, N. Li, J. Lv, et al., “PTMint Database of Experimentally Verified PTM Regulation on Protein-Protein Interaction,” Bioinformatics (Oxford, England) 39, no. 1 (2023): btac823.

[50] X. Hong, J. Lv, Z. Li, Y. Xiong, J. Zhang, and H. F. Chen, “Sequence-Based Machine Learning Method for Predicting the Effects of Phosphorylation on Protein-Protein Interactions,” International Journal of Biological Macromolecules 243 (2023): 125233.

[51] M. P. Torres, H. Dewhurst, and N. Sundararaman, “Proteome-Wide Structural Analysis of PTM Hotspots Reveals Regulatory Elements Predicted to Impact Biological Function and Disease,” Molecular & Cellular Proteomics: MCP 15, no. 11 (2016): 3513–3528.

[52] Ö. Karayel, P. Xu, I. Bludau, et al., “Integrative Proteomics Reveals Principles of Dynamic Phosphosignaling Networks in Human Erythropoiesis,” Molecular Systems Biology 16, no. 12 (2020): e9813.

[53] W. Gong, D. Zhou, Y. Ren, et al., “PepCyber:P∼PEP: A Database of Human Protein Protein Interactions Mediated by Phosphoprotein-Binding Domains,” Nucleic Acids Research 36, no. Database issue (2008): D679–D683.

[54] D. L. Brautigan, “Protein Ser/Thr Phosphatases–the Ugly Ducklings of Cell Signalling,” The FEBS Journal 280, no. 2 (2013): 324–345.

[55] A. Hershko and A. Ciechanover, “The Ubiquitin System,” Annual Review of Biochemistry 67 (1998): 425–479.

[56] S. Toma-Fukai and T. Shimizu, “Structural Diversity of Ubiquitin E3 Ligase,” Molecules (Basel, Switzerland) 26, no. 21 (2021): 6682.

[57] R. E. Lacoursiere, D. Hadi, and G. S. Shaw, “Acetylation, Phosphorylation, Ubiquitination (Oh My!): Following Post-Translational Modifications on the Ubiquitin Road,” Biomolecules 12, no. 3 (2022): 467.

[58] T. Oishi, S. Hatazawa, T. Kujirai, et al., “Contributions of Histone Tail Clipping and Acetylation in Nucleosome Transcription by RNA Polymerase II,” Nucleic Acids Research 51, no. 19 (2023): 10364–10374.

[59] M. A. Honer, B. I. Ferman, Z. H. Gray, E. A. Bondarenko, and J. R. Whetstine, “Epigenetic Modulators Provide a Path to Understanding Disease and Therapeutic Opportunity,” Genes & Development 38, no. 11-12 (2024): 473–503.

[60] H. Song, R. Shen, X. Liu, et al., “Histone Post-Translational Modification and the DNA Damage Response,” Genes & Diseases 10, no. 4 (2023): 1429–1444.

[61] P. Wong, S. M. Hattangadi, A. W. Cheng, G. M. Frampton, R. A. Young, and H. F. Lodish, “Gene Induction and Repression During Terminal Erythropoiesis Are Mediated by Distinct Epigenetic Changes,” Blood 118, no. 16 (2011): e128–e138.

[62] S. Sundaravel, U. Steidl, and A. Wickrema, “Epigenetic Modifiers in Normal and Aberrent Erythropoeisis,” Seminars in Hematology 58, no. 1 (2021): 15–26.

[63] E. F. Heuston, C. A. Keller, J. Lichtenberg, et al., “Establishment of Regulatory Elements During Erythro-Megakaryopoiesis Identifies Hematopoietic Lineage-Commitment Points,” Epigenetics & Chromatin 11, no. 1 (2018): 22.

[64] O. Kerscher, R. Felberbaum, and M. Hochstrasser, “Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins,” Annual Review of Cell and Developmental Biology 22 (2006): 159–180.

[65] W. Wang and M. J. Matunis, “Paralogue-Specific Roles of SUMO1 and SUMO2/3 in Protein Quality Control and Associated Diseases,” Cells 13, no. 1 (2023): 8.

[66] J. Eichler, “Protein Glycosylation,” Current Biology: CB 29, no. 7 (2019): R229–R231.

[67] A. S. Tsiftsoglou, “Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine,” Cells 10, no. 8 (2021): 2140.

[68] H. Neubauer, A. Cumano, M. Müller, H. Wu, U. Huffstadt, and K. Pfeffer, “Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis,” Cell 93, no. 3 (1998): 397–409.

[69] K. R. Gillinder, H. Tuckey, C. C. Bell, et al., “Direct Targets of pSTAT5 Signalling in Erythropoiesis,” PLoS ONE 12, no. 7 (2017): e0180922.

[70] Z. Tóthová, J. Tomc, N. Debeljak, and P. Solár, “STAT5 as a Key Protein of Erythropoietin Signalization,” International Journal of Molecular Sciences 22, no. 13 (2021): 7109.

[71] M. A. Held, E. Greenfest-Allen, S. Su, C. J. Stoeckert, M. P. Stokes, and D. M. Wojchowski, “Phospho-PTM Proteomic Discovery of Novel EPO- Modulated Kinases and Phosphatases, Including PTPN18 as a Positive Regulator of EPOR/JAK2 Signaling,” Cellular Signalling 69 (2020): 109554.

[72] W. Tong, J. Zhang, and H. F. Lodish, “Lnk Inhibits Erythropoiesis and Epo-Dependent JAK2 Activation and Downstream Signaling Pathways,” Blood 105, no. 12 (2005): 4604–4612.

[73] R. Morris, Y. Zhang, J. I. Ellyard, et al., “Structural and Functional Analysis of Target Recognition by the Lymphocyte Adaptor Protein LNK,” Nature Communications 12, no. 1 (2021): 6110.

[74] S. Comazzetto, M. M. Murphy, S. Berto, E. Jeffery, Z. Zhao, and S. J. Morrison, “Restricted Hematopoietic Progenitors and Erythropoiesis Require SCF From Leptin Receptor+ Niche Cells in the Bone Marrow,” Cell Stem Cell 24, no. 3 (2019): 477–486.e6.

[75] N. Haas, T. Riedt, Z. Labbaf, et al., “Kit Transduced Signals Counteract Erythroid Maturation by MAPK-Dependent Modulation of Erythropoietin Signaling and Apoptosis Induction in Mouse Fetal Liver,” Cell Death and Differentiation 22, no. 5 (2015): 790–800.

[76] M. C. Wilkes, A. Shibuya, and K. M. Sakamoto, “Signaling Pathways That Regulate Normal and Aberrant Red Blood Cell Development,” Genes 12, no. 10 (2021): 1646.

[77] L. Beuret, S. P. Fortier-Beaulieu, V. Rondeau, et al., “Mek1 and Mek2 Functional Redundancy in Erythropoiesis,” Frontiers in Cell and Developmental Biology 9 (2021): 639022.

[78] K. Ames, I. Kaur, Y. Shi, et al., “PI3-Kinase Deletion Promotes Myelodysplasia by Dysregulating Autophagy in Hematopoietic Stem Cells,” Science Advances 9, no. 8 (2023): eade8222.

[79] E. Beneduce, A. Matte, L. De Falco, et al., “Fyn Kinase Is a Novel Modulator of Erythropoietin Signaling and Stress Erythropoiesis,” American Journal of Hematology 94, no. 1 (2019): 10–20.

[80] E. F. Gautier, M. Leduc, S. Cochet, et al., “Absolute Proteome Quantification of Highly Purified Populations of Circulating Reticulocytes and Mature Erythrocytes,” Blood Advances 2, no. 20 (2018): 2646–2657.

[81] S. Zheng, N. A. Krump, M. M. McKenna, et al., “Regulation of Erythrocyte Na(+)/K(+)/2Cl(-) Cotransport by an Oxygen-Switched Kinase Cascade,” Journal of Biological Chemistry 294, no. 7 (2019): 2519–2528.

[82] Y. Okada, S. Chikura, T. Kimoto, and T. Iijima, “CDK4/6 Inhibitor-Induced Bone Marrow Micronuclei Might be Caused by Cell Cycle Arrest During Erythropoiesis,” Genes and Environment: The Official Journal of the Japanese Environmental Mutagen Society 46, no. 1 (2024): 3.

[83] Y. Hwang, M. Futran, D. Hidalgo, et al., “Global Increase in Replication Fork Speed During a p57(KIP2)-Regulated Erythroid Cell Fate Switch,” Science Advances 3, no. 5 (2017): e1700298.

[84] Y. Peng, L. Tang, Y. Li, et al., “Comprehensive Proteomic Analysis Reveals Dynamic Phospho-Profiling in Human Early Erythropoiesis,” British Journal of Haematology 199, no. 3 (2022): 427–442.

[85] A. T. Nguyen, M. A. Prado, P. J. Schmidt, et al., “UBE2O Remodels the Proteome During Terminal Erythroid Differentiation,” Science (New York, NY) 357, no. 6350 (2017): eaan0218.

[86] L. Cappadocia and C. D. Lima, “Ubiquitin-Like Protein Conjugation: Structures, Chemistry, and Mechanism,” Chemical Reviews 118, no. 3 (2018): 889–918.

[87] J. Lausen, O. Pless, F. Leonard, O. N. Kuvardina, B. Koch, and A. Leutz, “Targets of the Tal1 Transcription Factor in Erythrocytes: E2 Ubiquitin Conjugase Regulation by Tal1,” Journal of Biological Chemistry 285, no. 8 (2010): 5338–5346.

[88] D. Sherpa, J. Mueller, Ö. Karayel, et al., “Modular UBE2H-CTLH E2-E3 Complexes Regulate Erythroid Maturation,” Elife 11 (2022): e77937.

[89] M. E. R. Maitland, G. Onea, C. A. Chiasson, et al., “The Mammalian CTLH Complex Is an E3 Ubiquitin Ligase That Targets Its Subunit Muskelin for Degradation,” Scientific Reports 9, no. 1 (2019): 9864.

[90] R. Zhen, C. Moo, Z. Zhao, et al., “Wdr26 Regulates Nuclear Condensation in Developing Erythroblasts,” Blood 135, no. 3 (2020): 208–219.

[91] K. Yanagitani, S. Juszkiewicz, and R. S. Hegde, “UBE2O is a Quality Control Factor for Orphans of Multiprotein Complexes,” Science (New York, NY) 357, no. 6350 (2017): 472–475.

[92] C. S. Thom, E. A. Traxler, E. Khandros, et al., “Trim58 Degrades Dynein and Regulates Terminal Erythropoiesis,” Developmental Cell 30, no. 6 (2014): 688–700.

[93] T. Hosoya, M. Clifford, R. Losson, O. Tanabe, and J. D. Engel, “TRIM28 is Essential for Erythroblast Differentiation in the Mouse,” Blood 122, no. 23 (2013): 3798–3807.

[94] Y. J. Chang, Z. Kang, J. Bei, et al., “Generation of TRIM28 Knockout K562 Cells by CRISPR/Cas9 Genome Editing and Characterization of TRIM28-Regulated Gene Expression in Cell Proliferation and Hemoglobin Beta Subunits,” International Journal of Molecular Sciences 23, no. 12 (2022): 6839.

[95] R. Blaybel, O. Théoleyre, A. Douablin, and F. Baklouti, “Downregulation of the Spi-1/PU.1 Oncogene Induces the Expression of TRIM10/HERF1, a Key Factor Required for Terminal Erythroid Cell Differentiation and Survival,” Cell Research 18, no. 8 (2008): 834–845.

[96] C. Fan and X. Wang, “Mdm2 Splice Isoforms Regulate the p53/Mdm2/Mdm4 Regulatory Circuit via RING Domain-Mediated Ubiquitination of p53 and Mdm4,” Cell Cycle (Georgetown, Tex) 16, no. 7 (2017): 660–664.

[97] M. Maetens, G. Doumont, S. D. Clercq, et al., “Distinct Roles of Mdm2 and Mdm4 in Red Cell Production,” Blood 109, no. 6 (2007): 2630–2633.

[98] P. Xu, D. C. Scott, B. Xu, et al., “FBXO11-Mediated Proteolysis of BAHD1 Relieves PRC2-Dependent Transcriptional Repression in Erythropoiesis,” Blood 137, no. 2 (2021): 155–167.

[99] L. Liang, Y. Peng, J. Zhang, et al., “Deubiquitylase USP7 Regulates Human Terminal Erythroid Differentiation by Stabilizing GATA1,” Haematologica 104, no. 11 (2019): 2178–2187.

[100] Y. Yang, A. J. Kueh, Z. L. Grant, et al., “The Histone Lysine Acetyltransferase HBO1 (KAT7) Regulates Hematopoietic Stem Cell Quiescence and Self-Renewal,” Blood 139, no. 6 (2022): 845–858.

[101] J. Yang, J. Ma, Y. Xiong, et al., “Epigenetic Regulation of Megakaryocytic and Erythroid Differentiation by PHF2 Histone Demethylase,” Journal of Cellular Physiology 233, no. 9 (2018): 6841–6852.

[102] L. Xu, L. Zhang, J. Sun, et al., “Roles for the Methyltransferase SETD8 in DNA Damage Repair,” Clinical Epigenetics 14, no. 1 (2022): 34.

[103] J. Malik, M. Getman, and L. A. Steiner, “Histone Methyltransferase Setd8 Represses Gata2 Expression and Regulates Erythroid Maturation,” Molecular and Cellular Biology 35, no. 12 (2015): 2059–2072.

[104] J. A. Myers, T. Couch, Z. Murphy, J. Malik, M. Getman, and L. A. Steiner, “The Histone Methyltransferase Setd8 Alters the Chromatin Landscape and Regulates the Expression of Key Transcription Factors During Erythroid Differentiation,” Epigenetics & Chromatin 13, no. 1 (2020): 16.

[105] L. Yu, G. Myers, C. J. Ku, et al., “An Erythroid-to-Myeloid Cell Fate Conversion Is Elicited by LSD1 Inactivation,” Blood 138, no. 18 (2021): 1691–1704.

[106] J. Su, X. Wang, Y. Bai, M. Sun, Y. Yao, and Y. Duan, “The Role of MOZ/KAT6A in Hematological Malignancies and Advances in MOZ/KAT6A Inhibitors,” Pharmacological Research 174 (2021): 105930.

[107] C. Pessoa Rodrigues, J. S. Herman, B. Herquel, et al., “Temporal Expression of MOF Acetyltransferase Primes Transcription Factor Networks for Erythroid Fate,” Science Advances 6, no. 21 (2020): eaaz4815.

[108] L. Arede, E. Foerner, S. Wind, et al., “KAT2A Complexes ATAC and SAGA Play Unique Roles in Cell Maintenance and Identity in Hematopoiesis and Leukemia,” Blood Advances 6, no. 1 (2022): 165–180.

[109] Y. Feng, S. Borosha, A. Ratri, et al., “DOT1L Methyltransferase Regulates Calcium Influx in Erythroid Progenitor Cells in Response to Erythropoietin,” International Journal of Molecular Sciences 23, no. 9 (2022): 5137.

[110] M. Li, D. Liu, F. Xue, et al., “Stage-Specific Dual Function: EZH2 Regulates Human Erythropoiesis by Eliciting Histone and Non-Histone Methylation,” Haematologica 108, no. 9 (2023): 2487–2502.

[111] V. Migliori, S. Phalke, M. Bezzi, and E. Guccione, “Arginine/Lysine-Methyl/Methyl Switches: Biochemical Role of Histone Arginine Methylation in Transcriptional Regulation,” Epigenomics 2, no. 1 (2010): 119–137.

[112] S. C. Herkt, O. N. Kuvardina, J. Herglotz, et al., “Protein Arginine Methyltransferase 6 Controls Erythroid Gene Expression and Differentiation of Human CD34(+) Progenitor Cells,” Haematologica 103, no. 1 (2018): 18–29.

[113] S. M. Greenblatt, F. Liu, and S. D. Nimer, “Arginine Methyltransferases in Normal and Malignant Hematopoiesis,” Experimental Hematology 44, no. 6 (2016): 435–441.

[114] F. Zhu and L. Rui, “PRMT5 in Gene Regulation and Hematologic Malignancies,” Genes & Diseases 6, no. 3 (2019): 247–257.

[115] J. Malik, J. A. Lillis, T. Couch, M. Getman, and L. A. Steiner, “The Methyltransferase Setd8 Is Essential for Erythroblast Survival and Maturation,” Cell Reports 21, no. 9 (2017): 2376–2383.

[116] P. Ji, V. Yeh, T. Ramirez, M. Murata-Hori, and H. F. Lodish, “Histone Deacetylase 2 Is Required for Chromatin Condensation and Subsequent Enucleation of Cultured Mouse Fetal Erythroblasts,” Haematologica 95, no. 12 (2010): 2013–2021.

[117] Y. Wang, W. Li, V. P. Schulz, et al., “Impairment of Human Terminal Erythroid Differentiation by Histone Deacetylase 5 Deficiency,” Blood 138, no. 17 (2021): 1615–1627.

[118] P. Vong, H. Ouled-Haddou, and L. Garçon, “Histone Deacetylases Function in the Control of Early Hematopoiesis and Erythropoiesis,” International Journal of Molecular Sciences 23, no. 17 (2022): 9790.

[119] Y. Zhang, S. Xu, Z. Chen, et al., “Zfp521 SUMOylation Facilities Erythroid Hematopoietic Reconstitution Under Stress,” Bioscience, Biotechnology, and Biochemistry 84, no. 5 (2020): 943–953.

[120] M. Siatecka, L. Xue, and J. J. Bieker, “Sumoylation of EKLF Promotes Transcriptional Repression and Is Involved in Inhibition of Megakaryopoiesis,” Molecular and Cellular Biology 27, no. 24 (2007): 8547–8560.

[121] Y. C. Shyu, P. C. Liao, T. S. Huang, et al., “Genetic Disruption of KLF1 K74 SUMOylation in Hematopoietic System Promotes Healthy Longevity in Mice,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 9, no. 25 (2022): e2201409.

[122] L. Collavin, M. Gostissa, F. Avolio, et al., “Modification of the Erythroid Transcription Factor GATA-1 by SUMO-1,” Proceedings of the National Academy of Sciences of the United States of America 101, no. 24 (2004): 8870–8875.

[123] L. Yu, W. Ji, H. Zhang, et al., “SENP1-Mediated GATA1 deSUMOylation Is Critical for Definitive Erythropoiesis,” Journal of Experimental Medicine 207, no. 6 (2010): 1183–1195.

[124] M. Siatecka, S. Soni, A. Planutis, and J. J. Bieker, “Transcriptional Activity of Erythroid Kruppel-Like Factor (EKLF/KLF1) Modulated by PIAS3 (Protein Inhibitor of Activated STAT3),” Journal of Biological Chemistry 290, no. 15 (2015): 9929–9940.

[125] A. Iolascon, I. Andolfo, and R. Russo, “Congenital Dyserythropoietic Anemias,” Blood 136, no. 11 (2020): 1274–1283.

[126] A. Iolascon, G. D'Agostaro, S. Perrotta, P. Izzo, R. Tavano, and B. Miraglia del Giudice, “Congenital Dyserythropoietic Anemia Type II: Molecular Basis and Clinical Aspects,” Haematologica 81, no. 6 (1996): 543–559.

[127] B. E. Rosato, R. Marra, V. D'Onofrio, et al., “SEC23B Loss-of-Function Suppresses Hepcidin Expression by Impairing Glycosylation Pathway in Human Hepatic Cells,” International Journal of Molecular Sciences 23, no. 3 (2022): 1304.

[128] S. Luanpitpong, X. Kang, M. Janan, et al., “Metabolic Sensor O-GlcNAcylation Regulates Erythroid Differentiation and Globin Production via BCL11A,” Stem Cell Research & Therapy 13, no. 1 (2022): 274.

[129] S. Luanpitpong, K. Tangkiettrakul, X. Kang, et al., “OGT and OGA Gene-Edited Human Induced Pluripotent Stem Cells for Dissecting the Functional Roles of O-GlcNAcylation in Hematopoiesis,” Frontiers in Cell and Developmental Biology 12 (2024): 1361943.

[130] D. Pascovici, J. X. Wu, M. J. McKay, et al., “Clinically Relevant Post-Translational Modification Analyses-Maturing Workflows and Bioinformatics Tools,” International Journal of Molecular Sciences 20, no. 1 (2018): 16.

[131] P. Cifani and A. Kentsis, “Towards Comprehensive and Quantitative Proteomics for Diagnosis and Therapy of Human Disease,” Proteomics 17, no. 1-2 (2017):1600079.

[132] M. Dasari, J. A. Kurian, S. Gundraju, A. Raparthi, and R. V. Medapati, “Blood-Based β-Amyloid and Phosphorylated Tau (p-Tau) Biomarkers in Alzheimer's Disease: A Systematic Review of Their Diagnostic Potential,” Cureus 17, no. 3 (2025): e79881.

[133] X. Zhong, Q. Wang, M. Yang, et al., “Plasma p-tau217 and p-tau217/Aβ1-42 Are Effective Biomarkers for Identifying CSF- and PET Imaging-Diagnosed Alzheimer's Disease: Insights for Research and Clinical Practice,” Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21, no. 2 (2025): e14536.

[134] C. R. Jack, J. S. Andrews, T. G. Beach, et al., “Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's Association Workgroup,” Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20, no. 8 (2024): 5143–5169.

[135] S. P. Schauer, B. Toth, J. Lee, et al., “Pharmacodynamic Effects of Semorinemab on Plasma and CSF Biomarkers of Alzheimer's Disease Pathophysiology,” Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20, no. 12 (2024): 8855–8866.

[136] M. Sun, J. Li, L. Mao, et al., “p53 Deacetylation Alleviates Sepsis-Induced Acute Kidney Injury by Promoting Autophagy,” Frontiers in Immunology 12 (2021): 685523.

[137] L. Nie, L. Shuai, M. Zhu, et al., “The Landscape of Histone Modifications in a High-Fat Diet-Induced Obese (DIO) Mouse Model,” Molecular & Cellular Proteomics: MCP 16, no. 7 (2017): 1324–1334.

[138] P. Zhang, D. Wang, G. Zhou, et al., “Novel Post-Translational Modification Learning Signature Reveals B4GALT2 as an Immune Exclusion Regulator in Lung Adenocarcinoma,” Journal for Immunotherapy of Cancer 13, no. 2 (2025): e010787.

[139] P. Carrillo-Rodriguez, F. Selheim, and M. Hernandez-Valladares, “Mass Spectrometry-Based Proteomics Workflows in Cancer Research: The Relevance of Choosing the Right Steps,” Cancers 15, no. 2 (2023): 555.

[140] M. Stastna, “Post-Translational Modifications of Proteins in Cardiovascular Diseases Examined by Proteomic Approaches,” The FEBS Journal 292, no. 1 (2025): 28–46.

[141] L. Ramalhete, E. Vigia, R. Araújo, and H. P. Marques, “Proteomics-Driven Biomarkers in Pancreatic Cancer,” Proteomes 11, no. 3 (2023): 24.

[142] K. H. Ho, X. Yang, A. B. Osipovich, et al., “Glucose Regulates Microtubule Disassembly and the Dose of Insulin Secretion via Tau Phosphorylation,” Diabetes 69, no. 9 (2020): 1936–1947.

[143] J. Yao, K. Li, Z. Fu, et al., “Human Tau Promotes Warburg Effect-Like Glycolytic Metabolism Under Acute Hyperglycemia Conditions,” Journal of Biological Chemistry 301, no. 4 (2025): 108376.

[144] F. Tang, J. Wei, M. L. Wong, and P. Lei, “Tau Protein: Physiological Functions and Multifaceted Roles in Neurodegenerative and Psychiatric Disorders,” Genomic Psychiatry: Advancing Science From Genes to Society (2025).

[145] H. Wesseling, W. Mair, M. Kumar, et al., “Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease,” Cell 183, no. 6 (2020): 1699–1713.e13.

[146] D. Wang, X. Chen, K. Sui, et al., “UBE2O-Mediated Monoubiquitination Licenses NLRP6 Inflammasome Activation in the Intestine,” Cell Host & Microbe 34, no. 1 (2026): 86–102.e8.

[147] Z. Zhou, X. Zheng, J. Zhao, et al., “ULK1-Dependent Phosphorylation of PKM2 Antagonizes O-GlcNAcylation and Regulates the Warburg Effect in Breast Cancer,” Oncogene 43, no. 23 (2024): 1769–1778.

[148] Y. Lei, Q. Liu, B. Chen, et al., “Protein O-GlcNAcylation Coupled to Hippo Signaling Drives Vascular Dysfunction in Diabetic Retinopathy,” Nature Communications 15, no. 1 (2024): 9334.

[149] Y. Zhang, Z. Huang, K. Li, et al., “TrkA Promotes MDM2-Mediated AGPS Ubiquitination and Degradation to Trigger Prostate Cancer Progression,” Journal of Experimental & Clinical Cancer Research: CR 43, no. 1 (2024): 16.

[150] Y. Liu, W. Xun, T. Zhao, et al., “Interplay Between Acetylation and Ubiquitination Controls PSAT1 Protein Stability in Lung Adenocarcinoma,” Communications Biology 7, no. 1 (2024): 1365.

[151] E. Khandros, C. S. Thom, J. D'Souza, and M. J. Weiss, “Integrated Protein Quality-Control Pathways Regulate Free α-Globin in Murine β-Thalassemia,” Blood 119, no. 22 (2012): 5265–5275.

[152] S. Ponnikorn, T. Panichakul, K. Sresanga, et al., “Phosphoproteomic Analysis of Apoptotic Hematopoietic Stem Cells From Hemoglobin E/β-Thalassemia,” Journal of Translational Medicine 9 (2011): 96.

[153] M. B. Strader, S. Jana, F. Meng, et al., “Post-Translational Modification as a Response to Cellular Stress Induced by Hemoglobin Oxidation in Sickle Cell Disease,” Scientific Reports 10, no. 1 (2020): 14218.

[154] P. L. Tharaux, “Posttranslational Modifications of Sickle Hemoglobin in Microparticles May Promote Injury,” Kidney International 95, no. 6 (2019): 1289–1291.

[155] P. Noomuna, J. M. Hausman, R. Sansoya, T. Kalfa, M. Risinger, and P. S. Low, “Rapid Degradation of Protein Tyrosine Phosphatase 1B in Sickle Cells: Possible Contribution to Sickle Cell Membrane Weakening,” The FASEB Journal 36, no. 6 (2022): e22360.

[156] N. Alli, M. Coetzee, V. Louw, et al., “Sickle Cell Disease in a Carrier With Pyruvate Kinase Deficiency,” Hematology (Amsterdam, Netherlands) (Amsterdam, Netherlands) 13, no. 6 (2008): 369–372.

[157] J. Z. Xu and G. M. Vercellotti, “Pyruvate Kinase Activators: Targeting Red Cell Metabolism in Sickle Cell Disease,” Hematology American Society of Hematology Education Program 2023, no. 1 (2023): 107–113.

[158] M. J. M. Traets, J. F. Bos, S. van der Veen, et al., “Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease,” American Journal of Hematology 100, no. 5 (2025): 785–796.

[159] A. Barakat, R. Jasuja, L. Tomlinson, et al., “Effects of 2,3-DPG Knockout on SCD Phenotype in Townes SCD Model Mice,” American Journal of Hematology 98, no. 12 (2023): 1838–1846.

[160] C. James, V. Ugo, J. P. Le Couédic, et al., “A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera,” Nature 434, no. 7037 (2005): 1144–1148.

[161] J. Shi, B. Yuan, W. Hu, and H. Lodish, “JAK2 V617F Stimulates Proliferation of Erythropoietin-Dependent Erythroid Progenitors and Delays Their Differentiation by Activating Stat1 and Other Nonerythroid Signaling Pathways,” Experimental Hematology 44, no. 11 (2016): 1044–1058.

[162] T. Hricik, G. Federici, A. Zeuner, et al., “Transcriptomic and Phospho-Proteomic Analyzes of Erythroblasts Expanded in Vitro From Normal Donors and From Patients With Polycythemia Vera,” American Journal of Hematology 88, no. 9 (2013): 723–729.

[163] L. Da Costa, T. Leblanc, and N. Mohandas, “Diamond-Blackfan Anemia,” Blood 136, no. 11 (2020): 1262–1273.

[164] S. Rio, M. Gastou, N. Karboul, et al., “Regulation of Globin-Heme Balance in Diamond-Blackfan Anemia by HSP70/GATA1,” Blood 133, no. 12 (2019): 1358–1370.

[165] R. Roskoski, “Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2025 Update,” Pharmacological Research 216 (2025): 107723.

[166] B. Biswas, Y. H. Huang, D. J. Craik, and C. K. Wang, “The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance,” Chemical Science 15, no. 33 (2024): 13130–13147.

[167] Z. Zhao and P. E. Bourne, “Exploring Extended Warheads Toward Developing Cysteine-Targeted Covalent Kinase Inhibitors,” Journal of Chemical Information and Modeling 64, no. 24 (2024): 9517–9527.

[168] J. Sun, L. Lou, C. Zhu, et al., “Rationally Designed BCR-ABL Kinase Inhibitors for Improved Leukemia Treatment via Covalent and Pro-/Dual-Drug Targeting Strategies,” Journal of Advanced Research 74 (2025): 541–554.

[169] P. Y. Lee, Y. Yeoh, and T. Y. Low, “A Recent Update on Small-Molecule Kinase Inhibitors for Targeted Cancer Therapy and Their Therapeutic Insights From Mass Spectrometry-Based Proteomic Analysis,” The FEBS Journal 290, no. 11 (2023): 2845–2864.

[170] H. E. Hsu, M. J. Martin, S. H. Weng, et al., “Phosphoproteomics of Osimertinib-Tolerant Persister Cells Reveals Targetable Kinase-Substrate Signatures,” Molecular Systems Biology 21, no. 11 (2025): 1547–1562.

[171] P. Casado, S. Marfa, M. M. Hadi, et al., “Phosphoproteomics Identifies Determinants of PAK Inhibitor Sensitivity in Leukaemia Cells,” Cell Communication and Signaling: CCS 23, no. 1 (2025): 135.

[172] Y. N. Lamb, “Givinostat: First Approval,” Drugs 84, no. 7 (2024): 849–856.

[173] A. Raucci, C. Zwergel, S. Valente, and A. Mai, “Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential,” Journal of Medicinal Chemistry 68, no. 14 (2025): 14171–14194.

[174] S. Gold and A. Shilatifard, “Epigenetic Therapies Targeting Histone Lysine Methylation: Complex Mechanisms and Clinical Challenges,” The Journal of Clinical Investigation 134, no. 20 (2024): e183391.

[175] O. Sogbein, P. Paul, M. Umar, A. Chaari, V. Batuman, and R. Upadhyay, “Bortezomib in Cancer Therapy: Mechanisms, Side Effects, and Future Proteasome Inhibitors,” Life Sciences 358 (2024): 123125.

[176] P. Roth, T. Gorlia, J. C. Reijneveld, et al., “Marizomib for Patients With Newly Diagnosed Glioblastoma: A Randomized Phase 3 Trial,” Neuro-Oncology 26, no. 9 (2024): 1670–1682.

[177] E. K. Rowinsky, A. Paner, J. G. Berdeja, et al., “Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients With Relapsed and/or Refractory Multiple Myeloma,” Investigational New Drugs 38, no. 5 (2020): 1448–1453.

[178] J. T. Hwang, A. Lee, and C. Kho, “Ubiquitin and Ubiquitin-Like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases,” International Journal of Molecular Sciences 23, no. 9 (2022): 5053.

[179] F. Meng, Z. Liang, K. Zhao, and C. Luo, “Drug Design Targeting Active Posttranslational Modification Protein Isoforms,” Medicinal Research Reviews 41, no. 3 (2021): 1701–1750.

[180] H. Zhang, D. Xu, H. Huang, et al., “Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase,” ACS Chemical Biology 19, no. 4 (2024): 999–1010.

[181] Y. Peng, J. Liu, H. Inuzuka, and W. Wei, “Targeted Protein Posttranslational Modifications by Chemically Induced Proximity for Cancer Therapy,” Journal of Biological Chemistry 299, no. 4 (2023): 104572.

[182] J. Ge, C. Y. Hsieh, M. Fang, H. Sun, and T. Hou, “Development of PROTACs Using Computational Approaches,” Trends in Pharmacological Sciences 45, no. 12 (2024): 1162–1174.

[183] A. Tefferi and T. Barbui, “Polycythemia Vera: 2024 Update on Diagnosis, Risk-Stratification, and Management,” American Journal of Hematology 98, no. 9 (2023): 1465–1487.

[184] J. J. Kiladjian, P. Zachee, M. Hino, et al., “Long-Term Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Polycythaemia Vera (RESPONSE): 5-Year Follow Up of a Phase 3 Study,” The Lancet Haematology 7, no. 3 (2020): e226–e237.

[185] A. M. Vannucchi, J. J. Kiladjian, M. Griesshammer, et al., “Ruxolitinib Versus Standard Therapy for the Treatment of Polycythemia Vera,” The New England Journal of Medicine 372, no. 5 (2015): 426–435.

[186] P. Sadjadian, K. Wille, and M. Griesshammer, “Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations,” Cancers 12, no. 11 (2020): 3132.

[187] M. Mansilla-Polo and D. Morgado-Carrasco, “Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review,” Dermatology and Therapy 14, no. 8 (2024): 1983–2038.

[188] J. Q. Lin, S. Q. Li, S. Li, et al., “A 10-Year Retrospective Cohort Study of Ruxolitinib and Association With Nonmelanoma Skin Cancer in Patients With Polycythemia Vera and Myelofibrosis,” Journal of the American Academy of Dermatology 86, no. 2 (2022): 339–344.

[189] S. Verstovsek, S. Courby, M. Griesshammer, et al., “A Phase 2 Study of Momelotinib, a Potent JAK1 and JAK2 Inhibitor, in Patients With Polycythemia Vera or Essential Thrombocythemia,” Leukemia Research 60 (2017): 11–17.

[190] J. Berdeja, F. Palandri, M. R. Baer, et al., “Phase 2 Study of Gandotinib (LY2784544) in Patients With Myeloproliferative Neoplasms,” Leukemia Research 71 (2018): 82–88.

[191] S. Lugthart, C. Ginete, P. Kuona, M. Brito, and B. P. D. Inusa, “An Update Review of New Therapies in Sickle Cell Disease: The Prospects for Drug Combinations,” Expert Opinion on Pharmacotherapy 25, no. 2 (2024): 157–170.

[192] M. D. Cappellini, S. Sheth, A. T. Taher, et al., “ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults With Transfusion-Dependent Alpha- or Beta-Thalassemia,” Blood 144, no. Supplement 1 (2024): 409–409.

[193] M. J. van Dijk, M. A. E. Rab, B. A. van Oirschot, et al., “One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-Up Results of a Phase 2, Open-Label Study,” Blood Advances 7, no. 24 (2023): 7539–7550.

[194] J. Z. Xu, E. M. Novelli, J.-A. Ribeil, et al., “Results From a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients With Sickle Cell Disease,” Blood 144, no. Supplement 1 (2024): 2496–2496.

[195] S. L. Saraf, R. Hagar, M. Idowu, et al., “Multicenter, Phase 1 Study of Etavopivat (FT-4202) Treatment for up to 12 Weeks in Patients With Sickle Cell Disease,” Blood Advances 8, no. 16 (2024): 4459–4475.

[196] P. Noomuna, M. Risinger, S. Zhou, et al., “Inhibition of Band 3 Tyrosine Phosphorylation: A New Mechanism for Treatment of Sickle Cell Disease,” British Journal of Haematology 190, no. 4 (2020): 599–609.

[197] E. Federti, A. Matte, A. Recchiuti, et al., “In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury,” HemaSphere 7, no. 3 (2023): e848.

[198] M. Karimi, M. Bahadoram, L. Mafakher, and M. Rastegar, “Impact of Imatinib on Reducing the Painful Crisis in Patients With Sickle Cell Disease,” Hematology, Transfusion and Cell Therapy 46, no. 4 (2024): 387–392.

[199] K. Le, X. Wang, J. Chu, et al., “Activating Pyruvate Kinase Improves Red Blood Cell Integrity by Reducing Band 3 Tyrosine Phosphorylation,” Blood Advances 8, no. 21 (2024): 5653–5662.

[200] X. Wang, Y. Cho, N. Asomaning, et al., “Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients With Sickle Cell Disease Are Sustained During Extended Therapy,” Blood 144, no. Supplement 1 (2024): 2491–2491.

[201] S. Cui, K. C. Lim, L. Shi, et al., “The LSD1 Inhibitor RN-1 Induces Fetal Hemoglobin Synthesis and Reduces Disease Pathology in Sickle Cell Mice,” Blood 126, no. 3 (2015): 386–396.

[202] A. Rivers, K. Vaitkus, V. Ibanez, et al., “The LSD1 Inhibitor RN-1 Recapitulates the Fetal Pattern of Hemoglobin Synthesis in Baboons (P. Anubis),” Haematologica 101, no. 6 (2016): 688–697.

[203] A. Rivers, K. Vaitkus, R. Jagadeeswaran, et al., “Oral Administration of the LSD1 Inhibitor ORY-3001 Increases Fetal Hemoglobin in Sickle Cell Mice and Baboons,” Experimental Hematology 67 (2018): 60–64.e2.

[204] A. Rivers, K. Vaitkus, R. Jagadeeswaran, et al., “Oral Administration of the LSD1 Inhibitor OG-S1335 Increases Fetal Hemoglobin in Humanized Transgenic Sickle Cell Disease Mice and in Baboons,” Blood 130 (2017): 356.

[205] V. Ibanez, K. Vaitkus, X. Zhang, et al., “Combinatorial Targeting of Epigenome-Modifying Enzymes With Decitabine and RN-1 Synergistically Increases HbF,” Blood Advances 7, no. 15 (2023): 3891–3902.

[206] T. Nualkaew, P. Khamphikham, P. Pongpaksupasin, et al., “UNC0638 Induces High Levels of Fetal Hemoglobin Expression in β-Thalassemia/HbE Erythroid Progenitor Cells,” Annals of Hematology 99, no. 9 (2020): 2027–2036.

[207] S. Mettananda, C. A. Fisher, J. A. Sloane-Stanley, et al., “Selective Silencing of α-Globin by the Histone Demethylase Inhibitor IOX1: A Potentially New Pathway for Treatment of β-Thalassemia,” Haematologica 102, no. 3 (2017): e80–e84.

[208] P. Khamphikham, C. Wongborisuth, S. Pornprasert, et al., “IOX1 Fails to Reduce α-Globin and Mediates γ-Globin Silencing in Adult β(0)-Thalassemia/Hemoglobin E Erythroid Progenitor Cells,” Experimental Hematology 112–113 (2022): 9–14.e7.

[209] T. Fujiwara, H. Saitoh, A. Inoue, et al., “3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-Dependent Methyltransferase, Promotes Erythroid Differentiation,” Journal of Biological Chemistry 289, no. 12 (2014): 8121–8134.

[210] S. Mettananda, N. Yasara, C. A. Fisher, S. Taylor, R. Gibbons, and D. Higgs, “Synergistic Silencing of α-Globin and Induction of γ-Globin by Histone Deacetylase Inhibitor, Vorinostat as a Potential Therapy for β-Thalassaemia,” Scientific Reports 9, no. 1 (2019): 11649.

[211] M. M. Okam, E. B. Esrick, E. Mandell, F. Campigotto, D. S. Neuberg, and B. L. Ebert, “Phase 1/2 Trial of Vorinostat in Patients With Sickle Cell Disease Who Have Not Benefitted From Hydroxyurea,” Blood 125, no. 23 (2015): 3668–3669.

[212] A. Kutlar, N. Patel, C. Ustun, et al., “LBH589 (panobinostat): A Potential Novel Anti-Switching Therapy,” Blood 114, no. 22 (2009): 2568.

[213] H. T. Chifotides, P. Bose, and S. Verstovsek, “Givinostat: An Emerging Treatment for Polycythemia Vera,” Expert Opinion on Investigational Drugs 29, no. 6 (2020): 525–536.

[214] A. Rambaldi, A. Iurlo, A. M. Vannucchi, et al., “Long-Term Safety and Efficacy of Givinostat in Polycythemia Vera: 4-Year Mean Follow Up of Three Phase 1/2 Studies and a Compassionate Use Program,” Blood Cancer Journal 11, no. 3 (2021): 53.

[215] D. Su, H. Zhao, and H. Xia, “Glycosylation-Modified Erythropoietin With Improved Half-Life and Biological Activity,” International Journal of Hematology 91, no. 2 (2010): 238–244.

[216] R. O'Flaherty, M. Amez Martín, R. A. Gardner, et al., “Erythropoietin N-Glycosylation of Therapeutic Formulations Quantified and Characterized: An Interlab Comparability Study of High-Throughput Methods,” Biomolecules 14, no. 1 (2024): 125.

[217] C. N. Harrison, J. Nangalia, R. Boucher, et al., “Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41, no. 19 (2023): 3534–3544.

[218] V. Boldrini, A. M. Vannucchi, and P. Guglielmelli, “A Safety Evaluation of Ruxolitinib for the Treatment of Polycythemia Vera,” Expert Opinion on Drug Safety 23, no. 1 (2024): 1–7.

[219] E. Hexner, G. Roboz, R. Hoffman, et al., “Open-Label Study of Oral CEP-701 (lestaurtinib) in Patients With Polycythaemia Vera or Essential Thrombocythaemia With JAK2-V617F Mutation,” British Journal of Haematology 164, no. 1 (2014): 83–93.

[220] T. Doeven, E. J. Van Beers, R. van Wijk, et al., “Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients With Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II—Results From the 8-Week Dose-Escalation Period,” Blood 144, no. Supplement 1 (2024): 3831–3831.

[221] K. H. M. Kuo, D. M. Layton, A. Lal, et al., “Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults With Non-Transfusion Dependent α-Thalassaemia or β-Thalassaemia: An Open-Label, Multicentre, Phase 2 Study,” Lancet (London, England) 400, no. 10351 (2022): 493–501.

[222] T. Liu, A. K. Padyana, E. T. Judd, et al., “Structure-Based Design of AG-946, a Pyruvate Kinase Activator,” Chemmedchem 19, no. 5 (2024): e202300559.

[223] V. Ibanez, K. Vaitkus, M. A. Ruiz, et al., “Effect of the LSD1 Inhibitor RN-1 on γ-Globin and Global Gene Expression During Erythroid Differentiation in Baboons (Papio Anubis),” PLoS ONE 18, no. 12 (2023): e0289860.

[224] W. Kaewsakulthong, P. Pongpaksupasin, T. Nualkaew, et al., “Lysine-Specific Histone Demethylase 1 Inhibition Enhances Robust Fetal Hemoglobin Induction in Human β(0)-Thalassemia/Hemoglobin E Erythroid Cells,” Hematology Reports 13, no. 4 (2021): 9215.

[225] C. I. Papagiannopoulos, N. F. Theodoroula, K. A. Kyritsis, et al., “The Histone Methyltransferase Inhibitor A-366 Enhances Hemoglobin Expression in Erythroleukemia Cells Upon Co-Exposure With Chemical Inducers in Culture,” Journal of Biological Research (Thessalonike, Greece) 28, no. 1 (2021): 2.

[226] E. B. Esrick, M. McConkey, K. Lin, A. Frisbee, and B. L. Ebert, “Inactivation of HDAC1 or HDAC2 Induces Gamma Globin Expression Without Altering Cell Cycle or Proliferation,” American Journal of Hematology 90, no. 7 (2015): 624–628.

[227] M. A. Okhovat, K. Ziari, R. Ranjbaran, and N. Nikouyan, “The Effect of Histone Deacetylase Inhibitors on AHSP Expression,” PLoS ONE 13, no. 2 (2018): e0189267.

[228] L. H. Junker, B. Li, X. Zhu, et al., “Novel Histone Deacetylase Inhibitor CT-101 Induces γ-Globin Gene Expression in Sickle Erythroid Progenitors With Targeted Epigenetic Effects,” Blood Cells, Molecules & Diseases 93 (2022): 102626.

[229] C. Jalles, M. Lepelley, S. Mouret, J. Charles, M. T. Leccia, and S. Trabelsi, “Skin Cancers Under Janus Kinase Inhibitors: A World Health Organization Drug Safety Database Analysis,” Therapie 77, no. 6 (2022): 649–656.

[230] M. Rastrelli, B. Ferrazzi, S. Tropea, et al., “Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera,” In Vivo (Athens, Greece) 33, no. 5 (2019): 1667–1669.

[231] L. Hoisnard, B. Lebrun-Vignes, S. Maury, et al., “Adverse Events Associated With JAK Inhibitors in 126,815 Reports From the WHO Pharmacovigilance Database,” Scientific Reports 12, no. 1 (2022): 7140.

[232] E. A. Pedersen, M. E. Verhaegen, M. K. Joseph, K. L. Harms, and P. W. Harms, “Merkel Cell Carcinoma: Updates in Tumor Biology, Emerging Therapies, and Preclinical Models,” Frontiers in Oncology 14 (2024): 1413793.

[233] D. S. Parekh, W. A. Eaton, and S. L. Thein, “Recent Developments in the Use of Pyruvate Kinase Activators as a New Approach for Treating Sickle Cell Disease,” Blood 143, no. 10 (2024): 866–871.

[234] D. Lavelle, J. D. Engel, and Y. Saunthararajah, “Fetal Hemoglobin Induction by Epigenetic Drugs,” Seminars in Hematology 55, no. 2 (2018): 60–67.

[235] F. Liu, D. Barsyte-Lovejoy, F. Li, et al., “Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP,” Journal of Medicinal Chemistry 56, no. 21 (2013): 8931–8942.

[236] F. Palandri, G. Auteri, E. Abruzzese, et al., “Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The ”RAMP“ Italian Multicenter Prospective Study,” Annals of Hematology 103, no. 6 (2024): 1931–1940.

[237] D. Tremblay, L. Ronner, N. Podoltsev, et al., “Ruxolitinib Discontinuation in Polycythemia Vera: Patient Characteristics, Outcomes, and Salvage Strategies From a Large Multi-Institutional Database,” Leukemia Research 109 (2021): 106629.

[238] F. Palandri, G. A. Palumbo, E. M. Elli, et al., “Ruxolitinib Discontinuation Syndrome: Incidence, Risk Factors, and Management in 251 Patients With Myelofibrosis,” Blood Cancer Journal 11, no. 1 (2021): 4.

[239] R. F. Grace, C. Rose, D. M. Layton, et al., “Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency,” The New England Journal of Medicine 381, no. 10 (2019): 933–944.

[240] H. Huang, J. Niu, F. Wang, L. Hu, and Q. Yu, “A Natural Compound Derivative P-13 Inhibits STAT3 Signaling by Covalently Inhibiting Janus Kinase 2,” Investigational New Drugs 37, no. 3 (2019): 452–460.

[241] A. T. Negmeldin, J. R. Knoff, and M. K. H. Pflum, “The Structural Requirements of Histone Deacetylase Inhibitors: C4-Modified SAHA Analogs Display Dual HDAC6/HDAC8 Selectivity,” European Journal of Medicinal Chemistry 143 (2018): 1790–1806.

[242] R. Amirian, M. Azadi Badrbani, and Z. Izadi, “Targeted Protein Modification as a Paradigm Shift in Drug Discovery,” European Journal of Medicinal Chemistry 260 (2023): 115765.

[243] C. Bouvier, R. Lawrence, F. Cavallo, et al., “Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders,” Cells 13, no. 7 (2024): 578.

[244] N. Yang, B. Kong, Z. Zhu, et al., “Recent Advances in Targeted Protein Degraders as Potential Therapeutic Agents,” Molecular Diversity 28, no. 1 (2024): 309–333.

[245] A. T. S. Vicente and J. A. R. Salvador, “PROteolysis-Targeting Chimeras (PROTACs) in Leukemia: Overview and Future Perspectives,” MedComm 5, no. 6 (2024): e575.

[246] A. C. Lai, M. Toure, D. Hellerschmied, et al., “Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL,” Angewandte Chemie (International ed in English) 55, no. 2 (2016): 807–810.

[247] S. Mehta, A. Buyanbat, Y. Kai, et al., “Temporal Resolution of Gene Derepression and Proteome Changes Upon PROTAC-Mediated Degradation of BCL11A Protein in Erythroid Cells,” Cell Chemical Biology 29, no. 8 (2022): 1273–1287.e8.

[248] H. Yan, R. Zang, T. Cui, et al., “PROTAC-Mediated Vimentin Degradation Promotes Terminal Erythroid Differentiation of Pluripotent Stem Cells,” Stem Cell Research & Therapy 15, no. 1 (2024): 310.

[249] Y. Ravikumar, P. Koonyosying, S. Srichairatanakool, L. N. Ponpandian, J. Kumaravelu, and S. Srichairatanakool, “In Silico Molecular Docking and Dynamics Simulation Analysis of Potential Histone Lysine Methyl Transferase Inhibitors for Managing β-Thalassemia,” Molecules (Basel, Switzerland) (Basel, Switzerland) 28, no. 21 (2023): 7266.

[250] B. Pokharel, Y. Ravikumar, L. Rathinavel, et al., “The Discovery of Selective Protein Arginine Methyltransferase 5 Inhibitors in the Management of β-Thalassemia Through Computational Methods,” Molecules (Basel, Switzerland) (Basel, Switzerland) 29, no. 11 (2024): 2662.

[251] Y. Zhang, H. Yang, Y. Yu, and Y. Zhang, “Application of Nanomaterials in Proteomics-Driven Precision Medicine,” Theranostics 12, no. 6 (2022): 2674–2686.

[252] P. Yadav and S. Wairkar, “Tofacitinib in Focus: Fascinating Voyage From Conventional Formulations to Novel Delivery Systems,” International Journal of Pharmaceutics 671 (2025): 125253.

[253] M. Kühne, S. Hofmann, H. Lindemann, et al., “Analysis of HDACi-Coupled Nanoparticles: Opportunities and Challenges,” Methods in Molecular Biology (Clifton, NJ) 2589 (2023): 129–144.

[254] K. Y. Pham, S. Khanal, G. Bohara, et al., “HDAC6 Inhibitor-Loaded Brain-Targeted Nanocarrier-Mediated Neuroprotection in Methamphetamine-Driven Parkinson's Disease,” Redox Biology 79 (2025): 103457.

[255] L. Yao, N. Mustafa, E. C. Tan, et al., “Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat,” Journal of Medicinal Chemistry 60, no. 20 (2017): 8336–8357.

[256] X. Liang, J. Zang, X. Li, et al., “Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies,” Journal of Medicinal Chemistry 62, no. 8 (2019): 3898–3923.

[257] A. L. Sørensen, V. Skov, L. Kjær, et al., “Combination Therapy With Ruxolitinib and Pegylated Interferon Alfa-2a in Newly Diagnosed Patients With Polycythemia Vera,” Blood Advances 8, no. 20 (2024): 5416–5425.

[258] B. B. Sun, K. Suhre, and B. W. Gibson, “Promises and Challenges of Populational Proteomics in Health and Disease,” Molecular & Cellular Proteomics: MCP 23, no. 7 (2024): 100786.

[259] N. Varshney and A. K. Mishra, “Deep Learning in Phosphoproteomics: Methods and Application in Cancer Drug Discovery,” Proteomes 11, no. 2 (2023): 16.

[260] Y. Hernández-Reyes, M. C. Paz-Cabrera, R. Freire, and V. A. J. Smits, “USP29 Deubiquitinates SETD8 and Regulates DNA Damage-Induced H4K20 Monomethylation and 53BP1 Focus Formation,” Cells 11, no. 16 (2022): 2492.

[261] P. Vong, K. Messaoudi, N. Jankovsky, et al., “HDAC6 Regulates Human Erythroid Differentiation Through Modulation of JAK2 Signalling,” Journal of Cellular and Molecular Medicine 27, no. 2 (2023): 174–188.

[262] D. A. Hafez, I. A. Hassanin, M. Teleb, S. N. Khattab, K. A. Elkhodairy, and A. O. Elzoghby, “Recent Advances in Nanomedicine-Based Delivery of Histone Deacetylase Inhibitors for Cancer Therapy,” Nanomedicine (London, England) 16, no. 25 (2021): 2305–2325.

[263] J. L. Nickerson, V. Baghalabadi, S. Rajendran, et al., “Recent Advances in Top-Down Proteome Sample Processing Ahead of MS Analysis,” Mass Spectrometry Reviews 42, no. 2 (2023): 457–495.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.